V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Lung, Respiratory and Thoracic Cancer

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

Oncotarget.

Liu CY, Yang CT, Wang CL, Li SH, Hsu PC, Chen CH, Lin TY, Kuo CH, Fang YF, Ko HW, Yu CT, Yang TY

doi: 10.18632/oncotarget.18746.

Central Nervous System Tumors

A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor

Cancer Discov.

Wang J, Yao Z, Jonsson P, Allen AN, Qin ACR, Uddin S, Dunkel IJ, Petriccione M, Manova K, Haque S, Rosenblum MK, Pisapia DJ, Rosen N, Taylor BS, Pratilas CA

doi: 10.1158/

Breast Cancer

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Eur J Cancer.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group

doi: 10.1016/j.ejca.2017.05.010.

Gastrointestinal CancerGenitourinary CancerLung, Respiratory and Thoracic Cancer

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

BMC Cancer.

Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassineti GL, Ulivi P

doi: 10.1186/s12885-016-2463-2.

Lung, Respiratory and Thoracic Cancer

Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report

Clin Drug Investig.

Giusti R, Mazzotta M, Iacono D, Lauro S, Marchetti P

doi: 10.1007/s40261-017-0515-2.

Lung, Respiratory and Thoracic CancerRadio-Oncology

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports

Medicine (Baltimore).

Koba T, Kijima T, Takimoto T, Hirata H, Naito Y, Hamaguchi M, Otsuka T, Kuroyama M, Nagatomo I, Takeda Y, Kida H, Kumanogoh A

doi: 10.1097/

Lung, Respiratory and Thoracic Cancer

First-line treatment of ALK-positive NSCLC

healthbook TIMES Oncology Hematology

Bouchaab H

doi: 10.36000/hbT.OH.2019.02.008

Genitourinary Cancer

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Alexander Meisela,b

doi: 10.36000/hbT.OH.2019.02.007

Related content

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports

First-line treatment of ALK-positive NSCLC

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?